LimFlow system for late-stage chronic limb-threatening ischemia
Tests the LimFlow stent graft system in adults with severe leg artery disease.
Key facts
- Who runs it
- LimFlow, Inc.
- Where
- Albuquerque, Boston, Charlotte, Chicago, Cleveland, Dallas, Gainesville, Hershey, La Jolla, Lake Success, Lebanon, Milwaukee, Nashville, New Haven, New York, Norfolk, Palo Alto, Philadelphia, Pomona, San Francisco, St Louis, Tallahassee, Teaneck, Torrance, and Worcester, United StatesSee the 30 sites
- Trial code
- Registry title
- PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 22 Dec 2022
- Expected to end
- 1 May 2027
- Type of study
- Interventional
- Treatments tested
- LimFlow Stent Graft System
- Record updated
- 16 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with late-stage chronic limb-threatening ischemia, meaning very poor blood flow to a leg with a wound or gangrene. No usual bypass or other procedure to save the leg is possible for them. They will be treated with the LimFlow Stent Graft System.
- Age
- 18 to 95 years
- Sex
- All
- Disease stage
- Chronic limb-threatening ischemia with Rutherford Classification 5 (ulcer caused by poor blood flow) or 6 (gangrene). There must be severely reduced blood flow to the leg, for example ABI ≤ 0.39 or TP / TcPO2 < 30 mm Hg. The main wound must be stable. The artery used for the device must be within the size range set for the LimFlow stent graft.
- Earlier treatment
- The doctor must judge that no usual bypass, surgery or catheter treatment can save the leg. People with a prior leg artery bypass that would block blood flow to the device cannot join. People on dialysis can join only if on dialysis for > 6 months, with their own AV fistula or peritoneal access, serum albumin > 30 g/liter and BMI > 20.
- Biomarker or test result
- HbA1C < 10% (86 mmol/mol) (<269mg/dL). Women who could become pregnant need a negative pregnancy test within 7 days before joining.
Main reasons for not taking part
- Heart attack or stroke within the previous 90 days
- Active infection at the time of the procedure, or a life expectancy under 12 months
- Serum creatinine > 2.5 mg/dl (221 µmol/L) in people not on dialysis
- Severe heart failure (e.g., NYHA Class IV)
- Liver failure, a weak immune system or immune-suppressing treatment, or allergy to aspirin, P2Y12 inhibitors, heparin, stainless steel, nitinol or contrast agent
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Subject must be ≥ 18 and ≤ 95 years of age
- Clinical diagnosis of chronic limb-threatening ischemia, defined as any of the following clinical assessments: previous angiogram or hemodynamic evidence of severely diminished arterial inflow of the index limb (e.g., ABI ≤ 0.39, TP / TcPO2 < 30 mm Hg) and; Rutherford Classification 5, ischemic ulceration or; Rutherford Classification 6, ischemic gangrene
- Subject has been assessed by the Principal Investigator and determined that no conventional distal bypass, surgical or endovascular therapy for limb salvage is feasible due to either a) absence of a usable pedal artery target (endovascular or surgical approach), or b) the presence of a pedal artery target with absence of a viable single-segment vein in either lower extremity or either arm that could be used for autogenous vein conduit
- Proximally, the Target In-flow Artery at the cross-over point must fall within the recommended vessel diameter ranges for the LimFlow stent graft by visual estimation
- Subject is willing and able to sign the informed consent form
- Subject is enrolled in an acceptable wound care network and has an adequate support network to ensure that subject is compliant with medication regimen and follow-up study visits
- Prior to enrollment (7-day window), women of childbearing potential must have a negative pregnancy test
- Primary wound is stable (e.g., not rapidly deteriorating and/or showing signs of healing)
- Stable glycemic control, HbA1C < 10% (<269mg/dL)
- Subjects requiring dialysis may be included, provided they meet all the following requirements:; On dialysis for > 6 months; Autologous arteriovenous (AV) fistula or peritoneal access used for hemodialysis; Serum albumin > 30 g/liter; BMI > 20
Who cannot take part
- Concomitant hepatic insufficiency, thrombophlebitis in the target limb, or non-treatable coagulation disorder within the past 90 days
- Active immunodeficiency disorder or currently receiving immunosuppressant therapy for an immunodeficiency disorder
- Prior peripheral arterial bypass procedure above or below the knee which would inhibit proximal inflow to the stent graft
- Documented myocardial infarction or stroke within previous 90 days
- Known or suspected allergies or contraindications to aspirin or P2Y12 inhibitors, heparin, stainless steel, nitinol or contrast agent that cannot be adequately pre-treated
- Subject is currently taking anti-coagulants, which in the opinion of the investigator, interferes with the subject's ability to participate in the study (i.e., intermittent interruption of therapy for procedure may compromise subject's safety)
- Any significant concurrent medical, psychological, or social condition, which may significantly interfere with the subject's optimal participation in the study, in the opinion of the investigator
- The subject is currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study
- Lower extremity vascular disease that may inhibit the procedure and/or jeopardize wound healing (e.g., vasculitis, Buerger's disease, significant edema in the target limb, deep venous thrombus in the target vein, hyperpigmentation, or medial ulceration above the ankle)
- Severe heart failure (e.g., NYHA Class IV), which in the opinion of the investigator may compromise subject's ability to safely undergo a percutaneous procedure
- Active infection (e.g., fever, significantly elevated WBC count >20.0 x 109/L, and/or positive blood culture) at the time of the index procedure that may preclude insertion of a prosthesis or require major amputation (e.g., osteomyelitis proximal to metatarsals)
- Significant acute or chronic kidney disease with a serum creatinine of > 2.5 mg/dl in subjects not undergoing dialysis
- Absence of adequate viable tissue in target foot
- Life expectancy less than 12 months
- Subject is unwilling, unable, or unlikely for cognitive or social reasons to comply with any of the protocol or follow-up requirements
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 95 years old?
Where in United States
- Presbyterian HealthcareAlbuquerque, United StatesContact: Erin ToweryNo longer taking part
- Massachusetts General HospitalBoston, United StatesContact: Erin McSweeneyTaking people
- Boston Medical CenterBoston, United StatesContact: Erin ToweryNo longer taking part
- Atrium HealthCharlotte, United StatesContact: Erin ToweryNo longer taking part
- Rush University Medical CenterChicago, United StatesContact: Erin ToweryNo longer taking part
- University Hospitals Cleveland Medical Center*Cleveland, United StatesContact: Amy McKnightTaking people
- UT Southwestern Medical CenterDallas, United StatesContact: Erin ToweryNo longer taking part
- The Cardiac and Vascular InstituteGainesville, United StatesContact: Marti RobersonTaking people
- University of FloridaGainesville, United StatesContact: Erin ToweryNo longer taking part
- Penn State HealthHershey, United StatesContact: Erin ToweryNo longer taking part
- University of California San Diego HealthLa Jolla, United StatesContact: Erin ToweryNo longer taking part
- Northwell Health Long Island Jewish Medical CenterLake Success, United StatesContact: Sally KaplanTaking people
- Dartmouth Hitchcock Medical CenterLebanon, United StatesContact: Michelle KeyesTaking people
- Ascension Columbia St. Mary's HospitalMilwaukee, United StatesContact: Erin ToweryNo longer taking part
- The Medical College of WisconsinMilwaukee, United StatesContact: Erin ToweryNo longer taking part
- Vanderbilt University Medical CenterNashville, United StatesContact: Celia NunezTaking people
- Yale UniversityNew Haven, United StatesContact: Erin ToweryNo longer taking part
- Cornell UniversityNew York, United StatesContact: Erin ToweryNo longer taking part
- Mount SinaiNew York, United StatesContact: Erin ToweryNo longer taking part
- NYU Langone HealthNew York, United StatesContact: Erin ToweryNo longer taking part
- Sentara Norfolk General HospitalNorfolk, United StatesContact: Sarah HavertTaking people
- Stanford University, School of MedicinePalo Alto, United StatesContact: Erin ToweryNo longer taking part
- University of PennsylvaniaPhiladelphia, United StatesContact: Alice ChenTaking people
- Vascular Institute of Atlantic Medical ImagingPomona, United StatesContact: Erin ToweryNo longer taking part
- UCSFSan Francisco, United StatesContact: Erin ToweryNo longer taking part
- Washington University / Barnes JewishSt Louis, United StatesContact: Erin ToweryNo longer taking part
- Tallahassee Research InstituteTallahassee, United StatesContact: Erin ToweryNo longer taking part
- Holy Name Medical CenterTeaneck, United StatesContact: Erin ToweryNo longer taking part
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterTorrance, United StatesContact: Erin ToweryNo longer taking part
- UMass Chan Medical SchoolWorcester, United StatesContact: Erin ToweryNo longer taking part
About the trial
What the trial wants to find out
A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.
The group in the trial
- Treated with LimFlowTreatment being tested
Treatment with the LimFlow Stent Graft System
Treatment: LimFlow Stent Graft System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia: The PROMISE III Trial
- Plain-language title
- LimFlow system for late-stage chronic limb-threatening ischemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT05313165, who can take part
- Record updated
- 16 April 2026